Elevance Health (ELV) Q3 2026 Earnings Call: Q&A Summary

Q: What is the bridge to 12% earnings growth, is it dependent on Medicaid margin improvement, and what are the underlying cost trends?

A: Gail Boudreaux stated that confidence is driven by a higher earnings baseline of $26.75 and strong operating performance across the enterprise, noting that the company is not relying on any single business line to achieve its growth targets.

Q: Was Medicaid MLR up or down in the third quarter, and are rate improvements prospective or out-of-period?

A: Mark Kaye explained that Medicaid MLR was favorable due to July 1 rate actions, though underlying cost trends remain elevated and stable.

Q: How will work requirements impact Medicaid membership, acuity, and rates in 2027?

A: Felicia Norwood and Mark Kaye noted that states are still developing implementation plans, but 2027 rates are beginning to incorporate cost trends and potential acuity impacts from membership changes.

Q: Why is the Medicaid margin outlook only slightly ahead of previous guidance despite rate improvements, and is this due to investment or higher costs?

A: Mark Kaye and Gail Boudreaux clarified that while rate actions provided sequential margin uplift, the company is also executing on medical cost management and network performance to close the gap between rates and costs.

Q: How long will it take to reach target Medicaid margins, and what are the variables besides work requirements?

A: Mark Kaye stated that the pace of recovery to the 2% to 4% margin target depends on how quickly rates align with costs, with further details expected in January.

Q: What are the specific care management and clinical oversight actions driving Medicaid margin expansion, and what is the status of footprint rationalization?

A: Mark Kaye explained that the company is using AI-enabled analytics to identify inappropriate billing, strengthening behavioral health oversight, and aligning provider networks with affordability.

Q: What is driving CarelonRx outperformance, and what are the expectations for integrated medical and pharmacy in 2027?

A: Mark Kaye and Gail Boudreaux noted that CarelonRx performance was driven by PBM execution and dispensing assets, with integrated plans saving up to $100 per member per month.

Q: How much of Carelon's growth is internal versus external, and what is the outlook for the 2027 selling season?

A: Mark Kaye, Morgan Kendrick, and Gail Boudreaux reported that Carelon is scaling externally after proving value internally, with strong retention and a broad pipeline, and noted the appointment of Jeff Park as President of Carelon to lead further growth.

Q: Are Carelon risk businesses insulated from the broader medical cost pressure seen in the health benefits business?

A: Mark Kaye and Gail Boudreaux explained that Carelon is not fully insulated, but its financial results do not mirror health plan trends because of unique contract structures and clinical value generation, such as in behavioral health.

Q: How should investors interpret the focus on specialty pharmacy, and what is the capital deployment strategy?

A: Mark Kaye stated that the company remains disciplined with capital, prioritizing reinvestment and opportunistic M&A, while specialty pharmacy is central to CarelonRx's strategy of integrating medical and pharmacy management.

Q: What are the company's views on CMS guidelines for ABA therapy and what is within control regarding spend?

A: Felicia Norwood said the company is using AI to identify abnormalities in ABA therapy claims to ensure appropriate utilization while maintaining access to care.

Q: What is the medical cost trend for 2026, how is the company pricing for 2027, and what is the impact of IDR?

A: Mark Kaye stated that commercial cost trend is elevated but stable, and the company priced for a low double-digit trend while incorporating IDR experience into its assumptions.

Q: Does IDR continue to weigh on results, is the company pricing for margin expansion in Commercial, and what is the outlook for ACA margins?

A: Gail Boudreaux and Mark Kaye argued that the IDR process needs administrative changes due to excessive awards, while noting that commercial margins are expected to be stable and ACA margins are expected to improve.

Q: How did the ACA risk pool perform, and how do disenrollments impact market acuity?

A: Mark Kaye reported that ACA performance is ahead of expectations, and while the shift to bronze plans impacts risk adjustment, the company feels good about its position.

Q: What is driving the expected year-end ACA membership of 1.2 million, and how is the risk pool normalizing?

A: Mark Kaye explained that retention and effectuation rates have been better than expected, and the company expects the risk pool to take more than one renewal cycle to normalize.

Q: How does the company capture share as members shift to ASO-type membership and integrate Carelon products?

A: Morgan Kendrick and Gail Boudreaux stated that the company offers solutions for every geography and funding mechanism, with large employers increasingly seeking integrated solutions that include Carelon capabilities.

Q: Does the 12% earnings growth target assume Medicare Advantage margins return to target, and should Commercial risk enrollment contract further?

A: Felicia Norwood stated that the company is building off its 2026 Medicare Advantage margin of at least 2% and expects improvement in 2027 toward the 3% to 5% target range.